Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 0.56 |
| ▸ | NOS2 | P35228 | 12/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7690513 | 0.95 | SLC6A4 (0.53) | SLC6A4NOS2CYP2D6SLC6A2KCNH2 | |
| SCHEMBL6497216 | 0.95 | SLC6A4 (0.53) | SLC6A4NOS2CYP2D6SLC6A2KCNH2 | |
| Oxalic Acid SCHEMBL6500986 | 0.89 | NOS2 (0.72) | SLC6A4NOS2CYP2D6SLC6A2KCNH2 | |
| Oxalic Acid SCHEMBL6489765 | 0.89 | CYP2D6 (0.44) | SLC6A4NOS2CYP2D6SLC6A2KCNH2 | |
| Oxalic Acid SCHEMBL6499628 | 0.84 | SLC6A4 (0.77) | SLC6A4NOS2CYP2D6SLC6A2KCNH2 | |
| SCHEMBL6501468 | 0.84 | SLC6A4 (0.70) | SLC6A4NOS2CYP2D6SLC6A2KCNH2 | |
| SCHEMBL7608087 | 0.84 | SLC6A4 (0.70) | SLC6A4NOS2CYP2D6SLC6A2KCNH2 | |
| Oxalic Acid SCHEMBL6491863 | 0.83 | SLC6A4 (0.59) | SLC6A4NOS2CYP2D6SLC6A2KCNH2 | |
| SCHEMBL6493909 | 0.82 | SLC6A4 (0.38) | SLC6A4NOS2CYP2D6SLC6A2KCNH2 | |
| SCHEMBL7603066 | 0.82 | SLC6A4 (0.38) | SLC6A4NOS2CYP2D6SLC6A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | WARNER-LAMBERT COMPANY | 2005-07-14 | — | — | US | disclosed |
| US-6887871-B2 | Use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2005-05-03 | — | — | US | disclosed |
| US-20030158185-A1 | Novel use of phenylheteroakylamine derivatives | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | HMGCR, DHCR7, CYP11A1 | SLC6A4 4497/4885NOS2 1848/4885CYP2D6 880/4885 |
| US-20030158185-A1 | Novel use of phenylheteroakylamine derivatives | NOS1, XDH, NOS2 | SLC6A4 2468/4885NOS2 3/4885CYP2D6 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.